Roivant Sciences vs Tonix Pharmaceuticals
ROIV and TNXP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ROIV and TNXP compare
Roivant Sciences is the larger company, worth 553 times as much as Tonix Pharmaceuticals ($28.6B against $51.6M).
Tonix Pharmaceuticals grew revenue faster over the last twelve months (318% versus 102% for Roivant Sciences).
Tonix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −420% compared with −838% at Roivant Sciences.
Tonix Pharmaceuticals scores higher on the StockData Score (10 against 8 for Roivant Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ROIV | TNXP |
|---|---|---|
| Size and price | ||
| Market cap | $28.6B | $51.6M |
| Share price | $39.53 | $3.01 |
| Change, 1 year | 85.4% | −83.0% |
| Change, 5 years | 394% | −100.0% |
| Beta (5Y) | 0.85 | 2.01 |
| Employees | 721 | 142 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 2 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 695× | 1.2× (better) |
| P/B | 7.1× | 0.3× (better) |
| FCF yield | −0.12% (better) | −329% |
| Fair value | – | $18.27 |
| Margin of safety | – | 83.5% |
| Growth | ||
| Revenue growth (TTM) | 102% | 318% (better) |
| Revenue growth, 5Y average | −19.1% | – |
| Profitability | ||
| Gross margin | – | 89.3% |
| Operating margin | −1358% | −436% (better) |
| Net margin | −838% | −420% (better) |
| FCF margin | −81.2% (better) | −395% |
| Return on equity | −8.2% (better) | −84.1% |
| Return on invested capital | – | −388% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 15.56 (better) | 4.57 |
| Altman Z-score | 45.37 (better) | −6.62 |
| Piotroski F-score | 2 | 6 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −288% |
| Shareholder yield | 0.00% (better) | −288% |
| Ownership | ||
| Held by institutions | 78.1% | 54.6% |
| Held by insiders | 13.9% | 0.27% |
| Insider net buying, 12 months | −$798M | $479K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.3% | 19.4% |
Go deeper
- ROIV stock overview
- ROIV income statement
- ROIV valuation and score
- TNXP stock overview
- TNXP income statement
- TNXP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.